May 29, 2015 at 19:18 | Source: CNBC-TV18
Sarabjit Kour Nangra, VP- Research, Angel Broking, believes it to be the Ranbaxy effect. However, she says 14.5 percent is very low, because after consolidation she was looking at closer to 30 percent.
May 27, 2015 at 12:26 | Source: Moneycontrol.com
Taro Pharmaceutical Industries's fourth quarter net income grew by 70 percent to USD 152.3 million compared to USD 89.6 million in the year-ago period. Higher revenue, operational performance and forex income helped the bottomline.
Apr 28, 2015 at 11:32 | Source: Reuters
The just completed Ranbaxy deal, its biggest to date at USD 3.2 billion, has given India's biggest drugmaker sufficient scale in generics and emerging markets to think about its next step - beefing up expertise in higher margin products and gaining a bigger global presence.
Mar 12, 2015 at 15:07 | Source: Moneycontrol.com
Shares of Sun Pharmaceutical Industries and Ranbaxy Laboratories gained 2.5 percent each intraday on Thursday on news the Sun has formed new leadership team for merged entity.
Mar 12, 2015 at 14:34 | Source: PTI
While the leadership team is comprised mainly from the representatives of Sun Pharma, it also has executives from Ranbaxy, drawing upon expertise, experience and contribution of the chosen leaders from both the organisations.
Mar 04, 2015 at 17:48 | Source: PTI
In April last year, the 28-member European Union had temporarily banned import of Alphonso mangoes. It also banned import of four vegetables - taro, bitter gourd, snake gourd and eggplant - from India from May 1, 2014. Export of Indian mangoes to the EU during 2012 and 2013 were valued at USD 6.73 million and USD 10.09 million, respectively.
Feb 18, 2015 at 14:54 | Source: CNBC-TV18
The company has grown faster than the market in India and would be focused on research and development (R&D) spends going forward, said Uday Baldota, CFO, Sun Pharma.
Feb 11, 2015 at 11:49 | Source: Moneycontrol.com
Taro Pharmaceutical Industries, a subsidiary of Sun Pharma, has reported a 28.7 percent growth in bottomline during October-December quarter at USD 142.5 million on yearly basis. The bottomline growth was driven by revenue, gross margin and cost containment.
Dec 30, 2014 at 19:37 | Source: CNBC-TV18
2014 was a glitzy year for this man. With a net worth of USD 18 billion, 59-year-old Shanghvi became the second richest man in India, out-ranking Lakshmi Mittal on the Forbes India Rich List this year. Sun Pharma, a small start-up in 1983, leapfrogged to become the largest pharma company in India and fifth largest in the world.
Nov 14, 2014 at 11:59 | Source: CNBC-TV18
The pharma major is hopeful of maintaining its revenue growth guidance of 13-15 percent for FY15 though the margins may get impacted marginally.
Messages on Taro »


Platinum Member


Ranbaxy Labs  

One must understand that SUN cannot b redflagged bcs its main subsidiary is TARO is situated in Iserael which has more strintest practoces more than even USA.Also USA realised that by redflagging Indian cos like RBaxy it is USA public which is suffering bcs of nongen drugs produced by another

6.26 PM Jul 7th 2014


Platinum Member


Suven Life Scie  

That`s also a good strategy.Something I hear/read,even RJ follows.SLS management is conservative & Mr. Jasti has always been very candid about his company.Recently,they had achieved aprroval for Malathion,to be marketed by Taro.The bottomline will be 2MUSD every year from this product alone! See

9.23 PM Jul 3rd 2014


Silver Member


Sun Pharma  

Ultimately patience is paying rich dividends. Good to know Taro has shot up by more than 16%. Sun should open with a big gap monday morning. Cheers!

8.49 PM Jun 28th 2014


Gold Member


Sun Pharma  

Awsome Taro....16% up at 137 !! good news coming for sun pharma as well !!

6.53 PM Jun 28th 2014


Gold Member


Sun Pharma  

dear kurken...its other way buddy they will acquire mnc`s like taro,caraco,dusa etc...list not going to stop and its a professionally managed company...stay invested...

10.27 AM May 30th 2014


New Member



Guys: Hope you got benefitted by my buy call on Lupin today... all the pharma stocks buzzing Dr. Reddy, Lupin, Div lab... tomorrow sun pharma likely to post good results.. so continue buy Lupin as near term target is 960. Strong results of Taro is set to boost Sun Pharma`s Q4FY2014 results. Taro

4.06 PM May 28th 2014


New Member


Sun Pharmaceutical Industries  

Strong results of Taro is set to boost Sun Pharma`s Q4FY2014 results. Taro Pharma contributes near 48% of US revenue and 29% of total revenue. Sharekhan expect Sun Pharma to report a revenue of Rs4290 crore (39.7% YoY)and net profit of Rs1313 crore (29.8% YoY) in Q4FY2014. Sharekhan can expect

4.03 PM May 28th 2014

Sun Pharma  

Taro EPS up 44% for FY.

2.43 PM May 28th 2014

Sun Pharma  

Net income attributable to Taro was $360.4 million compared to $266.2 million, a $94.2 million increase, resulting in diluted earnings per share of $8.14 compared to $5.95 Net sales of $759.3 million, increased $88.3 million, or 13.2%, with a slight decrease in volumes Taro`s FY 14 results. EPS

2.42 PM May 28th 2014


New Member


Sun Pharma  

Taro posted spectacular results this time around. Sun Pharma will also post good results tomorrow. Exporters are doing good currently, so it is a good idea to buy sun pharma today, a combination of good results and short covering on expiry can easily take this stock to 600 levels. 580 can be used

1.54 PM May 28th 2014

News across the web »
Jul 22, 2015 at 14:59 | Source: FirstPost
Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.